<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005602</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL0012</org_study_id>
    <secondary_id>COG-ADVL0012</secondary_id>
    <secondary_id>CCG-ADVL0012</secondary_id>
    <secondary_id>ALK-01-042</secondary_id>
    <secondary_id>CCG-09802</secondary_id>
    <secondary_id>CDR0000067715</secondary_id>
    <nct_id>NCT00005602</nct_id>
  </id_info>
  <brief_title>Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas</brief_title>
  <official_title>Phase I Study of Concurrent Cereport and Carboplatin With Radiation Therapy for Children With Newly-Diagnosed Brain Stem Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as&#xD;
      carboplatin and lobradimil may make the tumor cells more sensitive to radiation therapy.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining radiation therapy with&#xD;
      carboplatin and lobradimil in treating children who have newly diagnosed brain stem gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated duration of lobradimil plus carboplatin with&#xD;
           radiotherapy in patients with newly diagnosed brain stem gliomas.&#xD;
&#xD;
        -  Determine the toxic effects of this treatment regimen in these patients.&#xD;
&#xD;
        -  Assess the response to radiotherapy in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive radiotherapy for 5 consecutive days a week for 6.5 weeks, for a&#xD;
      total of 33 doses. Patients receive carboplatin IV over 15 minutes followed by lobradimil IV&#xD;
      over 10 minutes concurrently with radiotherapy.&#xD;
&#xD;
      The first cohort of 3-6 patients receives treatment with carboplatin and lobradimil for the&#xD;
      first three weeks of radiotherapy, with the duration of chemotherapy increasing by one week&#xD;
      with each subsequent cohort until the maximum duration of 6.5 weeks is reached or until&#xD;
      unacceptable toxicity occurs in 2 of 6 patients.&#xD;
&#xD;
      Patients are followed at 6 weeks; every 3 months for 2 years; every 6 months for 3 years; and&#xD;
      then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-24 patients will be accrued for this study within 36 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <description>A MRI scan will be performed six (6) weeks after completion of radiation, plus at three-month intervals thereafter for two years, as long as there is no evidence of progressive disease. Children who are progression-free two years after treatment will have MRI scanning at six-month intervals, thereafter, for three more years</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days</arm_group_label>
    <other_name>Paraplatin</other_name>
    <other_name>CBDCA</other_name>
    <other_name>NSC #241240</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cereport</intervention_name>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days</arm_group_label>
    <other_name>labradimil</other_name>
    <other_name>IND #60315</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Newly diagnosed diffuse, intrinsic brain stem gliomas&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No disseminated disease at sites other than brain stem&#xD;
&#xD;
          -  No neurofibromatosis&#xD;
&#xD;
          -  Treatment must begin within 31 days of diagnosis&#xD;
&#xD;
               -  Date of diagnosis will be considered date of surgery in patients undergoing&#xD;
                  surgical biopsy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  3 to 21&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 50-100% (over 10 years of age)&#xD;
&#xD;
          -  Lansky 50-100% (10 years of age and under)&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGPT no greater than 2.5 times ULN (4.0 times ULN with antiepileptic or steroid&#xD;
             medications)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than ULN for age OR&#xD;
&#xD;
          -  Creatinine clearance or glomerular filtration rate greater than 80 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No history of severe allergic reaction to any platinum-containing compound&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent growth factors during therapy with carboplatin&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Prior corticosteroids for brain stem glioma are allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior surgery for brain stem glioma is allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 24 hours since any of the following medications:&#xD;
&#xD;
               -  Vasodilating compounds&#xD;
&#xD;
               -  Angiotensin-converting enzyme inhibitors&#xD;
&#xD;
               -  Calcium channel blockers&#xD;
&#xD;
               -  Beta blockers&#xD;
&#xD;
          -  No other prior therapy for brain stem glioma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger J. Packer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - LSU Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Clinical Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York - Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doernbecher Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated childhood brain stem glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

